We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
Internal Medicine - Tufts-New England Medical Center
Fellowships
Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center; Medicine - Weill Cornell Medical College
Board Certifications
Internal Medicine, Medical Oncology
I am a board-certified medical oncologist with expertise in donor-derived hematopoietic (blood-forming) stem cell transplantation. Hematopoietic stem cells from a donor other than the patient can cure many patients who have diseases of the blood and bone marrow, including leukemias and lymphomas. The donor stem cells can come from different sources (related or unrelated donors, and bone marrow, peripheral blood, or umbilical cord blood units) and can be modified in different ways before transplantation to enhance their effectiveness.
Read more
Along with colleagues here, I am participating in a number of studies designed to improve outcomes in patients undergoing stem cell transplantation, including finding ways to lower the risk of complications, relapse, and graft-versus-host disease. In particular, I am leading a clinical trial in patients who have advanced Hodgkin lymphoma; the goal of the trial is to determine the safest way to perform a transplant using stem cells from a donor in patients with relapsed Hodgkin lymphoma.
I also conduct translational clinical research investigating new ways to enhance the recovery of the immune system after a transplant and ways to help the immune system fight hematologic malignancies. My colleagues and I are investigating new agents such as interleukin-7 and KGF to enhance immune recovery, as well as new approaches to generate specialized T cells that will specifically target hematologic malignancies.
My practice consists of patients with a variety of hematologic malignancies who are in need of an allogeneic transplant, including patients with acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma. The goal of my practice and clinical research is to be able to offer every patient in need of a transplant the opportunity to undergo this potentially curative therapy.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Perales’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Miguel-Angel Perales discloses the following relationships and financial interests:
ADC Therapeutics Provision of Services
Bristol-Myers Squibb Provision of Services
Cidara Therapeutics, Inc. Provision of Services
CoImmune, Inc. Provision of Services
Equillium, Inc. Provision of Services
Incyte Provision of Services
Jazz Pharmaceuticals Provision of Services
Karyopharm Provision of Services
Kite Pharmaceuticals Provision of Services
Merck & Co Inc. Provision of Services
Miltenyi Biotec Incorporated Provision of Services
MorphoSys AG Provision of Services
NexImmune Ownership / Equity Interests; Provision of Services (uncompensated)
Novartis Provision of Services
Omeros Ownership / Equity Interests; Provision of Services
Orca Biosystems, Inc. Ownership / Equity Interests; Provision of Services (uncompensated)
Partners Therapeutics Inc. Provision of Services
VectivBio AG Provision of Services
Vor Biopharma Inc. Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
